nach oben

CNS Drugs

Erschienen in:

01.11.2005 | Review Article

Head-To-Head Comparison of the Costs of Atypical Antipsychotics

A Systematic Review

verfasst von: Corrado Barbui, Camilla Lintas, Dr Mauro Percudani

Erschienen in: CNS Drugs | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

In many countries, prescribing guidelines recommend the use of atypical or second-generation antipsychotics (SGAs) in the first-line treatment of individuals with newly diagnosed schizophrenia. This recommendation has increased the utilisation of these agents and, consequently, produced a progressive increase in the proportion of total direct costs in schizophrenia accounted for by drug therapy. In this still-evolving context of care, it becomes relevant to critically investigate the literature base on the relative cost effectiveness of each SGA in comparison with the others, the purpose being to ascertain whether the data reveal any one agent to be truly more cost effective than the others.

A systematic search of economic evaluations comparing two or more SGAs yielded 19 studies meeting the inclusion criteria. Of these, 11 were retrospective database or chart review analyses, six were observational prospective or mirror-image studies, and two were randomised clinical trials. Olanzapine and risperidone were compared in 16 studies, two studies compared clozapine, olanzapine and risperidone, and one compared clozapine and risperidone.

While experimental studies indicated an absence of differences among the SGAs in terms of total expenditure, database analyses found contrasting evidence. These latter studies, although susceptible to bias and confounding, should theoretically provide an added dimension, in that they are based on observations from ‘real world’ practice. However, there were too many potential threats to the validity of these analyses to draw a firm conclusion that any one agent is truly more cost effective than the others.

In this uncertain situation, clinicians and policy makers should be aware that indirect evidence from independent randomised controlled trials comparing individual SGAs with haloperidol suggested similar cost effectiveness. As healthcare providers in different settings are ultimately the ones who pay for new innovations, it seems appropriate that they commission research into the cost effectiveness of SGAs.

Freedman R. Schizophrenia. N Engl J Med 2004; 349: 1738–49

Llorca P-M, Chereau I, Bayle F-J, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129–38PubMedCrossRef

Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1995; 53: 313–9CrossRef

Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacologic basis of therapeutics. New York: McGraw-Hill Press, 2001

Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576–80PubMedCrossRef

Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990–9PubMed

Taylor D, McConnell D, McConnell H, et al. The Maudsley prescribing guidelines. 6th ed. London: Martin Dunitz, 2001

Barbui C, Danese A, Guaiana G, et al. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 2002; 6: 239–43CrossRef

Kapur S, Remington G. Atypical antipsychotics: patients value the lower incidence of extrapyramidal side effects. BMJ 2000; 321: 1360–1PubMedCrossRef

10.

Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomised controlled trials. Schizophr Res 1999; 35: 51–68PubMedCrossRef

11.

Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6PubMedCrossRef

12.

Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6): 553–64PubMedCrossRef

13.

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRef

14.

Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219–29PubMedCrossRef

15.

Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17PubMedCrossRef

16.

Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 702–6PubMedCrossRef

17.

EMEA. European Agency for the Evaluation of Medicinal Products public statement on the safety of olanzapine. European Agency for the Evaluation of Medicinal Products 2004, EMEA/CPMP/856/04/Final

18.

Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypothesis for an underlying mechanism. J Am Med Dir Assoc 2004; 5: 129–32PubMedCrossRef

19.

Wooltorton E. Risperidone: increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 26: 1269–70

20.

Wooltorton E. Olanzapine: increased incidence of cerebrovascular events in dementia trials [commentary]. CMAJ 2004; 170: 1395PubMedCrossRef

21.

Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500–8PubMedCrossRef

22.

Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161: 1–56

23.

Mortimer AM. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur Psychiatry 2003; 18: 209–19PubMedCrossRef

24.

Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509–18PubMedCrossRef

25.

Rouillon F, Dansette GY, Le Floch C. Etude de la prise en charge therapeutique des schizophrenes et de son cout. L’Encephale 1994; 20: 303–9PubMed

26.

Evers SM, Ament AJ. Costs of schizophrenia in the Netherlands. Schizophr Bull 1995; 21: 141–53PubMedCrossRef

27.

Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51: 1–18CrossRef

28.

Percudani M, Gerzeli S, Massagrandi R, et al. Costi ed esito dell’assistenza nei soggetti con disturbo mentale grave [Costs and outcome of care in subjects with a severe mental disorder]. Epidemiol Psichiatr Soc 2003; 12: 175–86PubMedCrossRef

29.

Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212–4PubMedCrossRef

30.

Birch S, Gaffni A. Cost-effectiveness and cost-utility analyses: methods for the non-economic evaluation of healthcare programs and how we can do better. In: Geisler E, Heller O, editors. Managing technology in healthcare. Norwell (MA): Kluwer Academic, 1996

31.

Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001; 322: 1596–8PubMedCrossRef

32.

Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalisation in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004; 3: 1–11CrossRef

33.

Byerly MJ, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003; 54: 742–4PubMedCrossRef

34.

Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567–79PubMedCrossRef

35.

Fuller MA, Shermock KM, Secic M, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv 2002; 53: 855–60PubMedCrossRef

36.

Gibson PJ, Damier R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004; 7: 22–35PubMedCrossRef

37.

Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002; 28: 589–605PubMedCrossRef

38.

Kasper S, Jones M, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia: health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 189–96PubMedCrossRef

39.

Kelly DL, Nelson MW, Love RC, et al. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 2001; 52: 676–8PubMedCrossRef

40.

Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62: 749–56PubMedCrossRef

41.

Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 2003; 64: 1293–9PubMedCrossRef

42.

Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998; 20: 1203–17PubMedCrossRef

43.

Rascati KL, Johnsrud MT, Crismond ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21: 683–97PubMedCrossRef

44.

Shermock KM, Sadik MK, Kozma CM, et al. Risperidone, haloperidol and clozapine in the South Carolina Medicaid Program. Dis Manage Health Outcomes 2001; 9: 203–13CrossRef

45.

Snaterse M, Welch R. A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine. Clin Drug Invest 2000; 20: 159–64CrossRef

46.

Taylor DM, Wright T, Libretto SE, et al. Risperidone compared with olanzapine in a naturalistic clinical study: a cost-analysis. J Clin Psychiatry 2003; 64: 589–97PubMedCrossRef

47.

Verma S, Orengo CA, Kunik ME, et al. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int J Geriatr Psychiatry 2001; 16: 223–7PubMedCrossRef

48.

Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six veterans affairs hospitals. Psychiatr Serv 1999; 50: 163–8PubMed

49.

Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002; 15: 75–81PubMed

50.

Zhao Z, Namjoshi M, Barber BL, et al. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine. CNS Drugs 2004; 18(3): 157–64PubMedCrossRef

51.

Kasper S, Rosillon D, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia: efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 179–87PubMedCrossRef

52.

Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editors. Measuring mental health. London: Gaskell, 1992: 163–83

53.

Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. J Clin Psychiatry 1993; 54Suppl. 5: 29–37PubMed

54.

Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

55.

Essock SM, Frisman LK, Covell NH, et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987–94PubMedCrossRef

56.

Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337: 809–15PubMedCrossRef

57.

Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693–702PubMedCrossRef

58.

Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999; 60Suppl. 19: 38–45PubMed

Titel: Head-To-Head Comparison of the Costs of Atypical Antipsychotics
A Systematic Review
verfasst von: Corrado Barbui
Camilla Lintas
Dr Mauro Percudani
Publikationsdatum: 01.11.2005
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2005
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200519110-00004

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2005

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

Rotigotine

Rotigotine

The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis

The Use of Triptans in the Management of Menstrual Migraine

Rotigotine

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Update Neurologie